Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Buprenorphine
Criminal justice settings
MOUD
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)
Medications for opioid use disorder
Methadone
Naltrexone
Opioid use disorder
Research protocol
Journal
Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
01
09
2020
revised:
09
12
2020
accepted:
02
01
2021
pubmed:
24
1
2021
medline:
27
8
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
A major driver of the U.S. opioid crisis is limited access to effective medications for opioid use disorder (MOUD) that reduce overdose risks. Traditionally, jails and prisons in the U.S. have not initiated or maintained MOUD for incarcerated individuals with OUD prior to their return to the community, which places them at high risk for fatal overdose. A 2018 law (Chapter 208) made Massachusetts (MA) the first state to mandate that five county jails deliver all FDA-approved MOUDs (naltrexone [NTX], buprenorphine [BUP], and methadone). Chapter 208 established a 4-year pilot program to expand access to all FDA-approved forms of MOUD at five jails, with two more MA jails voluntarily joining this initiative. The law stipulates that MOUD be continued for individuals receiving it prior to detention and be initiated prior to release among sentenced individuals where appropriate. The jails must also facilitate continuation of MOUD in the community on release. The Massachusetts Justice Community Opioid Innovation Network (MassJCOIN) partnered with these seven diverse jails, the MA Department of Public Health, and community treatment providers to conduct a Type 1 hybrid effectiveness-implementation study of Chapter 208. We will: (1) Perform a longitudinal treatment outcome study among incarcerated individuals with OUD who receive NTX, BUP, methadone, or no MOUD in jail to examine postrelease MOUD initiation, engagement, and retention, as well as fatal and nonfatal opioid overdose and recidivism; (2) Conduct an implementation study to understand systemic and contextual factors that facilitate and impede delivery of MOUDs in jail and community care coordination, and strategies that optimize MOUD delivery in jail and for coordinating care with community partners; (3) Calculate the cost to the correctional system of implementing MOUD in jail, and conduct an economic evaluation from state policy-maker and societal perspectives to compare the value of MOUD prior to release from jail to no MOUD among matched controls. MassJCOIN made significant progress during its first six months until the COVID-19 pandemic began in March 2020. Participating jail sites restricted access for nonessential personnel, established other COVID-19 mitigation policies, and modified MOUD programming. MassJCOIN adapted research activities to this new reality in an effort to document and account for the impacts of COVID-19 in relation to each aim. The goal remains to produce findings with direct implications for policy and practice for OUD in criminal justice settings.
Identifiants
pubmed: 33483222
pii: S0740-5472(21)00001-5
doi: 10.1016/j.jsat.2021.108275
pmc: PMC8263807
mid: NIHMS1663458
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108275Subventions
Organisme : NIDA NIH HHS
ID : K23 DA049953
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA050067
Pays : United States
Investigateurs
Sheriff Kevin F Coppinger
(SKF)
Jason Faro
(J)
Sheriff Christopher J Donelan
(SCJ)
Edmond Hayes
(E)
Sheriff Nicholas Cocchi
(SN)
Martha Lyman
(M)
Thomas Lincoln
(T)
Sheriff Patrick J Cahillane
(SPJ)
Melinda Cady
(M)
Sheriff Peter J Koutoujian
(SPJ)
Kashif Siddiqi
(K)
Dan Lee
(D)
Sheriff Jerome P McDermott
(SJP)
Tara Flynn
(T)
Erika Sica
(E)
Sheriff Steven W Tompkins
(SSW)
Rachelle Steinberg
(R)
Marjorie Bernadeau-Alexandre
(M)
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
J Subst Abuse Treat. 2017 Oct;81:25-34
pubmed: 28847452
Am J Public Health. 2018 Dec;108(12):1675-1681
pubmed: 30359112
J Subst Abuse Treat. 2021 May;124:108216
pubmed: 33288348
Health Care Manage Rev. 2020 Apr/Jun;45(2):151-161
pubmed: 29944489
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
J Subst Abuse Treat. 2013 Aug;45(2):222-6
pubmed: 23541303
Subst Abus. 2012;33(1):9-18
pubmed: 22263709
J Subst Abuse Treat. 2018 Aug;91:57-68
pubmed: 29910015
Drug Alcohol Depend. 2009 Jan 1;99(1-3):222-30
pubmed: 18930603
Drug Alcohol Depend. 2019 Dec 1;205:107514
pubmed: 31614328
J Subst Abuse Treat. 1997 Sep-Oct;14(5):445-55
pubmed: 9437614
Drug Alcohol Depend. 2010 Apr 1;108(1-2):98-109
pubmed: 20071107
Implement Sci. 2019 Jan 5;14(1):1
pubmed: 30611302
Addiction. 2016 Dec;111(12):2079-2081
pubmed: 27412876
Int J Drug Policy. 2020 Jul;81:102768
pubmed: 32446130
Drug Alcohol Depend. 2001 Jan 1;61(2):195-206
pubmed: 11137285
Health Justice. 2019 Dec 12;7(1):19
pubmed: 31832801
Am J Drug Alcohol Abuse. 2019;45(1):1-10
pubmed: 30675818
J Offender Rehabil. 2012 May 1;51(4):222-238
pubmed: 25392605
J Subst Abuse Treat. 2015 Mar;50:50-8
pubmed: 25456091
Adm Policy Ment Health. 2011 Jan;38(1):4-23
pubmed: 21197565
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Drug Alcohol Depend. 2014 Sep 1;142:33-40
pubmed: 24962326
Health Justice. 2018 Apr 13;6(1):9
pubmed: 29654518